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Abstract—Drug repositioning (DR) refers to identification of
novel indications for the approved drugs. The requirement of
huge investment of time as well as money and risk of failure in
clinical trials have led to surge in interest in drug repositioning.
DR exploits two major aspects associated with drugs and diseases:
existence of similarity among drugs and among diseases due to
their shared involved genes or pathways or common biological
effects. Existing methods of identifying drug-disease association
majorly rely on the information available in the structured
databases only. On the other hand, abundant information avail-
able in form of free texts in biomedical research articles are not
being fully exploited. Word-embedding or obtaining vector repre-
sentation of words from a large corpora of free texts using neural
network methods have been shown to give significant performance
for several natural language processing tasks. In this work we
propose a novel way of representation learning to obtain features
of drugs and diseases by combining complementary information
available in unstructured texts and structured datasets. Next we
use matrix completion approach on these feature vectors to learn
projection matrix between drug and disease vector spaces. The
proposed method has shown competitive performance with state-
of-the-art methods. Further, the case studies on Alzheimer’s and
Hypertension diseases have shown that the predicted associations
are matching with the existing knowledge.
Keywords—Representation Learning, Vector Representation,
Drug repositioning, Word vector, Heterogeneous Inference
I. INTRODUCTION
Development of new drugs is associated with huge invest-
ment of time and money, and risk of failure in clinical trials.
It has been estimated that on an average, drug development
process takes 15 years [1] and associated cost is approximately
$1 billion [2]. Finding novel indications for approved drugs,
referred as drug repositioning or drug repurposing(DR), has
attracted researchers and pharmaceutical industry as a cost-
effective and faster alternative to overcome this challenge [3].
The candidates for drug repositioning are drugs which are
already in market or which have been discontinued due to
various reasons other than safety issues. As per the estimate
in [3], DR allows a significant reduction in time from 10-17
years to 3-12 years in novel drug discovery. According to [4],
among all the drugs which have been approved by the US Food
and Drug Administration (FDA), approximately 30% of them
were the result of drug repositioning. Significant examples of
drug repositioning includes Aspirin (regular use as analgesic
and now also being widely adapted to treat heart related disease
[5]), Plerixafor (initially developed to treat HIV but later being
used as a drug to mobilize stem cells [6]), and Thalidomide
(initially developed to treat nausea but after drug repositioning
research, being used to treat dermatological issues and the
myelome disease [7]).
There have been significant number of methods developed
for the drug repositioning problem including machine learning
methods. We summarize the prominent methods in the sec-
tion V. Working principle of all methods rely on two important
aspects related to drugs and diseases. First, drugs often bind
to multiple targets resulting into various biological effects
including side-effects [8]. Second, a biological target of a drug
which is relevant to a particular disease, may also be directly
or indirectly associated with other diseases. In other words,
overlapping pathways or common associated targets between
various diseases are important factors and thereby making it
possible that an approved drug for one disease may be useful
in treating a similar disease [9].
Existing methods of identifying drug-disease association
majorly rely on the information available in the structured
databases only. However these databases are unable to keep
pace with the exponential growth of information appearing in
research articles. In this paper, our primary aim is to develop
a method which can exploit information present in free texts
as well as in structured databases. In recent years, vector
representation of words, learned using neural network based
methods from a large corpora of free texts, have been shown
to give significant performance for several natural language
processing tasks. Word vectors thus obtained are also shown
to capture syntactic and semantic properties. We employ a
novel method to learn representation of each drug and disease
terms which then are projected on a common vector space to
obtain similarity between drugs and diseases. Towards this end,
first we learn vector representation of drugs and diseases by
using the knowledge present in literature. Next, these vectors
are updated to accommodate various similarity measures of
drugs and diseases respectively. The resultant drug and disease
vector representation are not necessarily in the same vector-
space. So we employ matrix completion approach [10] to
learn a projection matrix between drug and disease vector
space. We evaluate the performance of our method using
ten fold cross validation and top k rank threshold methods
and compare it with 3 other competitive methods. We further
perform case studies on Alzheimer’s disease and Hypertension
and verify our predictions for these diseases from literature.
Our study shows that all our top ten drugs predicted for
Alzheimer’s disease are approved to treat neurodegenerative
diseases. Similarly 7 out 10 drugs predicted for Hypertension
are approved and 2 out of remaining 3 are used to treat Ocular
Hypertension.
II. MATERIALS AND METHODS
In this study we describe the datasets used. Later we
explain our method which includes learning the feature vector
and learning the projection matrix between drug and disease
vector space.
A. Dataset
This section discusses all datasets and their sources used
in this work.
1) Drug-Disease Association Data-
We use the same drug-disease association data as
used in PREDICT [11]. Data is made available as the
supplementary material of the corresponding paper
[11]. It contains 1933 drug-disease associations be-
tween 593 drugs and 313 diseases. All 593 drugs are
registered in DrugBank [12] and all 313 diseases are
listed in OMIM [13] database. As we have mentioned
earlier that the proposed method rely on obtaining
word embedding for each drug and disease from
a huge corpus of biomedical articles, we discarded
some drugs and diseases which we were not present
in the corpus. Finally we consider 584 drugs, 294
diseases and 1854 drug-disease associations known
between them.
2) SIDER: Drug Side Effect Data- We obtain the list
of side effects corresponding to all 584 drugs from
the SIDER [14] database.
3) Chemical Fingerprint of Drugs- Chemical finger-
print of a drug corresponds to the record of com-
ponent fragment present in their chemical structure.
For each drug their chemical fingerprint was obtained
from the DrugBank [12].
4) DrugBank- Similar to the chemical fingerprint of
drugs, drug targets are obtained from the DrugBank.
Drug targets one or more cellular molecules such as
metabolites or proteins for desired effects. A list of
targets corresponding to all 584 drugs are obtained.
5) DisGeNet: Disease Associated Genes- We collect
genes associated with disease from DisGeNET [15].
B. Construction of similarity measures
We calculate three types of similarity for drugs which are
based upon side-effects, chemical structure and target proteins.
Two similarities are calculated for each disease pair based upon
the disease phenotypes and associated genes.
1) Drug Similarity measures:
I Side effect similarity : A side effect is an undesired
consequence of a drug. Drugs cause side-effects
when they bind to off-target apart from their desired
on-targets. Under the assumption that if 2 drugs
share side-effects and hence off-targets, there is a
possibility that they might share on-targets which
can be used to cure diseases. Studies [16] show that
drugs sharing off targets might also share on targets.
For each drug pair (di, dj), this similarity is :
Sim(di, dj) =
|SE(di) ∩ SE(dj)|
|SE(di) ∪ SE(dj)|
where SE(d) is the set of side-effects related to drug
d.
II Chemical Similarity : Similarity of two chemicals is
based upon comparing their chemical fingerprint. A
fingerprint is a record of component fragment present
in a chemical structure. It has been shown in [17]
that Tanimoto coefficient can be an effective measure
to calculate similarity between two chemicals based
on their structures. Pairwise similarity between two
drugs was calculated as Tanimoto score of their
fingerprint using RDKit [18] library of Python.
III Drug-Target Similarity : A biological target is the
protein in the body which is either up regulated or
down regulated due to the action of a particular drug
on it . If two drugs share same targets, the probability
of them causing the similar effect may also increase.
Pairwise drug-target similarity between drugs di and
dj is calculated as :
Sim(di, dj) =
1
|P (di)||P (dj)|
P (di)∑
i=1
P (dj)∑
j=1
SW (P (di), P (dj))
where P (d) denotes the set of genes associated to
drug d and SW is the Smith-Waterman Sequence
alignment score [19].
2) Disease Similarity measures:
I Phenotypic similarity : A phenotypic feature is an
observable biological or clinical characteristic of a
disease. It is a amalgamation of gene expression as
well as influence of external environmental factors.
The similarity is collected from MIMMiner Tool
[20]. The tool measures disease similarity by comput-
ing similarity between MeSH terms [21] that appear
in the medical description of diseases in the OMIM
database.
II Gene Similarity : Disease causing or associated genes
are collected from DisGeNET [15]. Pairwise gene
similarity between disease di and dj is calculated as:
Sim(di, dj) =
1
|P (di)||P (dj)|
P (di)∑
i=1
P (dj)∑
j=1
SW (P (di), P (dj))
where P (d) denotes the set of genes associated to
disease d and SW is the Smith-Waterman Sequence
alignment score [19].
C. Method
The proposed method has three major steps. In the first step
we obtain vector representation of drugs and diseases using
neural embedding method [22]. We update these representa-
tions using similarity scores calculated from the various struc-
tured datasets. And in the last step, we learn a projection matrix
between the two vector-spaces so that a final association score
between drug-disease pair can be obtained. It is noteworthy
Fig. 1. Diagram depicting the flow of our method. First, the drug and disease
feature vector are learned. To do this, drug word vector and disease word vector
are updated using the similarity measures. Second, the projection matrix is
learned by using the well known associations and our drug/disease feature
vectors.
to mention here again that there is no requirement of negative
datasets. Figure 1 summarizes the proposed method.
1) Word vectors for drugs and diseases: To capture the
information present in literature, we obtain the word vector
representation of drugs and diseases. We use Pubmed [23] open
access set as our corpus. Each disease is mapped to its OMIM
id. As diseases can appear under various names in Pubmed
[23] corpus, each disease in the corpus is mapped to a Concept
Unique Identifier(CUI) by using UMLS Meta thesaurus [24].
If a disease (OMIM indication) has multiple concept names
associated to it, then the resultant vector is taken as the simple
average of all the vectors associated to that OMIM indication.
The concept names for each OMIM indication is obtained from
Supplementary Information of PREDICT [11]. Word vector
representation of each drug and disease is obtained by training
Pubmed Corpus using word2Vec [25] Python library. To train
vectors, we set window size to 5. We have experimented using
various vector dimensions ranging from 100 to 200.
2) Learning vector representation by combining similarity
measures: Let Nd be the number of drugs and Ns be the
number of diseases. Each drug word vector is denoted as
di ∈ R
N , where i ranges from 1 to Nd. Each disease word
vector is denoted as si ∈ R
N , where i ranges from 1 to Ns.
Let the updated drug vector (feature vector) for ith drug be
denoted as d˜i, which is initialized to di. Let the updated disease
vector (feature vector) for ith disease be denoted as s˜i, which
is initialized to si. Let Simk(i, j) denote the k
th similarity
between drug i and drug j or disease i and disease j.
Let M be the number of drug similarity measures and
L be the number of disease similarity measures. The motive
is to obtain a feature vector for each drug and disease by
combining the above mentioned similarities and updating the
word vectors. For each drug i ( i varies from 1 to Nd), d˜i is
updated when the below objective ( J1 ) is minimized:
J1 =
Nd∑
j=1
M∑
k=1
(
d˜i.dj
|d˜i||dj |
− Simk(i, j))
2
where |di| denote the length of the vector di .
Each drug word vector is updated using all the other
drug vectors and for each similarity measure. The updated
set of drug vectors (called feature vectors) is denoted as
D = [d˜1, d˜2, ..., ˜dNd ], where each d˜i ∈ R
N .
Similar kind of objective ( J2 ) is minimized for all disease
s˜i, where i varies from 1 to Ns .
J2 =
Ns∑
j=1
L∑
k=1
(
s˜i.sj
|s˜i||sj |
− Simk(i, j))
2
where |si| denote the length of the vector si.
Each disease word vector is updated using all the other
disease vectors and for each similarity measure. The updated
set of disease vectors (called feature vectors) is denoted as
S = [s˜1, s˜2, ..., ˜sNs ], where each s˜i ∈ R
N .
The optimization problem is solved using Theano [26]
library of Python. We have obtained a drug vector space and
a disease vector space where each vector is of dimension RN .
3) Learning projection from drug vector space to disease
vector space: Our motive is to learn a projection matrix from
drug vector space to disease vector space which will help us
in predicting drug-disease association scores. The projection
matrix should be such that the projected drug vectors are
geometrically close to vectors of their well known disease
vectors. The drugs that are in proximity in the directions of
their feature vectors may share diseases and vice-versa. Let
I ∈ RNd×Ns be called the association matrix where Iij is 1 if
drugi treats diseasej else 0. The projection matrix is denoted
as Z ∈ RN×N .
To learn this projection matrix we use inductive matrix
completion approach [10][27] which minimizes the following
objective function:
min
G,H
∑
i,j
||Iij − d˜iGH
T s˜j
T ||2 +
λ
2
(||G||2 + ||H ||2)
where the projection matrix Z = GHT , where G ∈ RN×K
and H ∈ RN×K . The score of a drug i and disease j pair is
calculated as:
score(i, j) = d˜iZs˜j
T
Higher the score, greater is the possibility of drug i treating
disease j .
III. EXPERIMENTS
We conduct 10-fold cross-validation experiments to eval-
uate the performance of all methods. We use AUC, ROC
and top-rank thresholds as evaluation metrics. In the top-rank
threshold measure, a well known drug-disease association is
considered as correctly predicted if its rank based on the
predicted score is within the specified rank threshold.
A. Baseline Methods
We compare the proposed method with three other meth-
ods, MBIRW [28], HGBI [29] and TP-NRWRH [30]. We
briefly summarize each of the three methods for the sake of
completeness.
The HGBI method creates a heterogeneous network of two
different type of nodes. One set of nodes are representing
different drugs and another set of nodes represent targets.
Edges exist between within same node types as well as be-
tween two different node types. Existence of edge depends on
drug-drug similarities, target-target similarities and drug-target
interactions. The edge weights of the network are updated in
an iterative fashion by incorporating all the paths between the
drug-target pair.
The MBIRW method constructs two separate networks on
drugs and diseases. Both similarity networks were created
using novel similarity measure which takes into account corre-
lation between different similarities. Further MBIRW performs
bi-directional random walk on these two networks to get scores
for drug disease associations.
TP-NRWH again uses random walk method but on single
heterogeneous drug-disease network. This network is similar
to the network used in the the HGBI method and integrates all
the similarity measures (drug-drug and disease-disease) and
well known drug-disease associations. This is in contrast to
the MBIRW method which creates two separate networks on
drugs and diseases.
We use default parameter settings for all the three methods.
Parameters of TP-NRWRH are set as (α = 0.3, λ = 0.8, η =
0.4). For MBIRW α is set to default 0.3 and max iterations
for right and left random walk is set to 2. For HGBI, restart
probability α is set to default 0.4 and cut off was set to 0.3.
IV. RESULTS
A. Vector representation
First we analyze the performance of our method with
respect to varying length of feature vectors between 100 and
200. Fig 2 shows AUC obtained by using different size of drugs
and disease vectors. Although increasing dimension generally
led to improved AUC score but improvement was not really
significant. Next we analyze the importance of updating the
word vectors based on similarity scores. We obtain an AUC
score of 0.77 when word-vectors obtained using word2vec
method on biomedical copora are not updated. On the other
hand an AUC score of 0.86 is obtained when updated word-
vectors are used. The relative improvement of 10% clearly
indicates that the vectors learned through our method captured
the similarity of drugs and diseases in better manner.
B. Comparison with existing methods
Fig 3 shows the AUC values and the ROC of 10-fold
cross-validation experiments. Although the proposed method
has obtained AUC value of 0.86 which is better than the one
obtained by HGBI (0.79) but the other two methods were
best performing methods. Similar observations are made based
on the top-rank threshold metric. The number of correctly
predicted associations by our method is greater than that of
HGBI for every top rank thresholds as shown in the Fig 4.
Fig. 2. Performance of our method in terms of AUC with respect to different
dimensionality of feature vector of drugs and diseases.
Fig. 3. Diagram depicting the Receiver operating characteristics of our
method and 3 other competitive methods. The AUC values are also mentioned.
C. Case Studies
After finding the performance of our model, we conducted
leave-disease-out experiment. For this, first we select a dis-
ease and train our model only with the remaining data after
excluding all known associations related to it. Then scores
are calculated for the held out disease and top scoring drugs
are reported. We perform the case studies on two diseases,
Alzheimer and Hypertension.
1) Alzheimer’s Disease: Table I shows the top scoring
Fig. 4. Diagram depicting the number of correctly predicted associations
with respect to five different top-ranked thresholds.
TABLE I. TOP 10 PREDICTED DRUGS FOR ALZHEIMER’S
DISEASE BY OUR METHOD
Rank Drug Name
Predicted
Score
Clinical
Evidence
Mean Score
1 Rivastigmine 0.31896 Yes 0.00090
2 Galantamine 0.21839 Yes 0.00274
3 Donepezil 0.20712 Yes 0.00669
4 Memantine 0.19311 Yes 0.00671
5 Ropinirole 0.15378 No 0.01309
6 Tacrine 0.14735 Yes 0.00309
7 Entacapone 0.14210 No 0.00625
8 Valproic Acid 0.14069 Yes 0.01276
9 Pramipexole 0.12957 No -0.00299
10 Carbidopa 0.12407 No 0.00282
TABLE II. TOP 10 PREDICTED DRUGS FOR HYPERTENSION
BY OUR METHOD
Rank Drug Name
Predicted
Score
Clinical
Evidence
Mean Score
1 Dyphylline 0.33169 No 0.01341
2 Trandolapril 0.30106 Yes 0.01325
3 Prazosin 0.27290 Yes 0.01150
4 Mecamylamine 0.26114 Yes 0.01084
5 Brinzolamide 0.26103 No 0.01857
6 Travoprost 0.25957 No 0.00937
7 Labetalol 0.25421 Yes 0.01268
8 Captopril 0.25322 Yes 0.01211
9 Losartan 0.25189 Yes 0.01750
10 Valsartan 0.24950 Yes 0.00656
drugs predicted by the model for Alzheimer’s disease.
Out of the top 10 drugs predicted by our method, 6
drugs namely Rivastigmine, Galantamine, Donepezil,
Memantine, Tacrine and Valproic Acid have been ap-
proved for Alzheimer’s disease. Other drugs namely
Ropinirole, Entacapone, Pramipexole and Carbidopa
have been used to treat Parkinson’s disease. Although
there is a difference in pathogenesis of Parkinson’s
disease and Alzheimer’s disease, but both of them
are neuro-degenerative disease associated with ag-
ing [31]. Pramipexole has been under Phase 2 of
Clinical trials (NCT01388478) [32] for the treatment
of Alzheimer’s disease. The above results have been
verified from PREDICT [11] and DrugBank [12].
2) Hypertension: Another indication, Hypertension was
analysed and its top scoring drugs are shown in
Table II. Out of the top 10 drugs predicted by
our method, 7 drugs namely Trandolapril, Prazosin,
Mecamylamine, Labetalol, Captopril, Losartan and
Valsartan are approved drugs for hypertension. Brin-
zolamide and Travoprost have been used for treating
ocular hypertension. The scores of these top predicted
drugs for treating Hypertension and Alzheimer’s dis-
ease are much higher than the mean score of these
drugs for all diseases.
V. RELATED WORK
Several computational methods have been developed to
solve the drug repositioning problem including machine learn-
ing as well as literature mining based methods. Literature
mining methods mainly rely on co-occurrence of drug, disease
and targets within a context [33][34]. These methods generally
have poor performance as they do not use any contextual
semantic information and treat all types of relations between
two relevant terms equivalently. On the other hand, machine
learning based models have been shown to perform relatively
better than co-occurrence based methods. Gottlieb et al. [11]
developed a logistic regression based model and combined
various similarity measures of drugs and diseases in order
to predict drug-disease associations. Wang et al. [35] applied
Support Vector Machine model on drug chemical structures,
protein sequences and disease phenotypic data in order to
identify new relations between drugs and diseases. One of the
major issue faced by these methods is requirement of negative
data, which is not available.
Network based models are good alternative as they do
not require both positive and negatively labeled data. Chiang
et al. developed a network based model which predict novel
indications for drugs based upon the fact that if two disease
share treatment profiles, then drugs approved for one of those
disease may be used to treat the other disease too. The
method relied upon ”guilt by association” technique [36].
Wang et al. developed a novel method which consists of three-
layer heterogeneous graph model to integrate relationships
between drugs, diseases and targets. Based on this model, an
iterative algorithm was used in order to rank drugs for each
disease. The method measures the strength between unlinked
drug-target pairs by using all the paths in the network [37].
Martinez et al. developed the DrugNet method, a network -
based prioritization method, that utilizes the information of
drugs, diseases and drug targets and performs prioritization
of drug-disease and disease-drug [38] associations. Lee et al.
exploited the structural properties of biological networks. They
developed shared neighborhood scoring algorithm and applied
it on an integrated drug-protein-disease tripartite network in
order to predict new indications for drugs [39]. Chen et al.
utilized already existing recommendation systems ProbS and
Heats to give recommendation score for disease with respect
to drugs [40]. Wu et al. constructed a weighted heterogeneous
network of drugs and diseases and applied clustering technique
using ClusterONE [41] algorithm to predict new drug-disease
associations [42]. Luo et al. improved drug-drug and disease-
disease similarity measures by using concepts of clustering and
by performing various analysis on similarity values. Further
they performed a bi-random walk on the similarity network
and well known drug-disease associations and learned drug-
disease association matrix [28].
VI. CONCLUSION
In this paper we have presented a novel representation
learning method to obtain vector representation of drugs and
diseases. These representations are then utilized to obtain
association score between drug-disease pairs. The main con-
tribution of this work is combining complementary informa-
tion available in unstructured texts and structured datasets.
Heterogeneous information was combined and feature vectors
were learned for drugs and diseases. Prediction using updated
feature vectors gave better results than using the original
word vectors. Case studies on Hypertension and Alzheimer’s
disease indicate that predictions made by our method can be
used for biomedical research. We compared our method with
existing methods on drug repositioning. Our results are fairly
comparable to those methods in terms of AUC and top k rank
threshold scoring mechanism.
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